uniQure (NASDAQ:QURE) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of uniQure (NASDAQ:QURE) from a hold rating to a sell rating in a report issued on Saturday morning,Wall Street Zen reports.

Other equities analysts have also issued reports about the company. Royal Bank Of Canada lifted their price objective on uniQure from $35.00 to $65.00 and gave the stock an “outperform” rating in a research note on Thursday, June 18th. The Goldman Sachs Group increased their target price on uniQure from $14.00 to $46.00 and gave the company a “neutral” rating in a research note on Thursday, June 18th. Wolfe Research raised uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 target price on the stock in a report on Wednesday, July 29th. Barclays dropped their price target on uniQure from $65.00 to $60.00 and set an “overweight” rating on the stock in a research report on Thursday, July 30th. Finally, Mizuho upped their price target on uniQure from $35.00 to $68.00 and gave the stock an “outperform” rating in a report on Thursday, June 25th. Fourteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $65.00.

uniQure Price Performance

NASDAQ QURE opened at $44.50 on Friday. uniQure has a 1 year low of $8.73 and a 1 year high of $71.50. The company has a fifty day simple moving average of $44.24 and a 200 day simple moving average of $30.57. The company has a current ratio of 10.01, a quick ratio of 10.01 and a debt-to-equity ratio of 0.15. The company has a market cap of $3.09 billion, a P/E ratio of -11.10 and a beta of 0.94.

uniQure (NASDAQ:QURE) last announced its earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.40). uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%.The firm had revenue of $5.84 million during the quarter, compared to the consensus estimate of $5.45 million. During the same quarter last year, the business earned ($0.69) EPS. On average, sell-side analysts predict that uniQure will post -3.82 EPS for the current year.

Insider Transactions at uniQure

In other news, Director Jack Kaye sold 21,167 shares of uniQure stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $46.44, for a total transaction of $982,995.48. Following the sale, the director owned 25,996 shares of the company’s stock, valued at approximately $1,207,254.24. This trade represents a 44.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Madhavan Balachandran sold 11,685 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $45.06, for a total value of $526,526.10. Following the sale, the director owned 43,254 shares in the company, valued at approximately $1,949,025.24. This represents a 21.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 385,584 shares of company stock worth $16,737,722 over the last 90 days. Insiders own 4.65% of the company’s stock.

Institutional Investors Weigh In On uniQure

Institutional investors have recently bought and sold shares of the business. Hennion & Walsh Asset Management Inc. boosted its position in shares of uniQure by 107.3% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 142,113 shares of the biotechnology company’s stock valued at $6,546,000 after acquiring an additional 73,566 shares in the last quarter. Royal Bank of Canada increased its stake in uniQure by 26.0% in the first quarter. Royal Bank of Canada now owns 107,888 shares of the biotechnology company’s stock valued at $1,763,000 after acquiring an additional 22,248 shares during the period. Kalehua Capital Management LLC bought a new stake in uniQure in the first quarter valued at about $4,760,000. Voss Capital LP raised its position in uniQure by 68.0% in the fourth quarter. Voss Capital LP now owns 210,000 shares of the biotechnology company’s stock worth $5,025,000 after purchasing an additional 85,000 shares in the last quarter. Finally, UBS Group AG raised its position in uniQure by 139.7% in the fourth quarter. UBS Group AG now owns 491,454 shares of the biotechnology company’s stock worth $11,760,000 after purchasing an additional 286,465 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.